This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global peptide synthesis market.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Download PDF Brochure@
COVID-19 impact on the Peptide Synthesis Market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The COVID-19 pandemic has increased the burden on healthcare systems across the globe. According to the WHO, there were 271,963,258 confirmed cases of COVID-19, including 5,331,019 deaths (as of December 17, 2021). The highest number of deaths was in the Americas, followed by Europe and Southeast Asia.
The COVID-19 pandemic has prompted key pharmaceutical and biotechnology companies and players in the peptide synthesis market to invest in therapeutic and peptide-based vaccine R&D. The rising demand for vaccines and peptide-based drugs has brought peptide synthesis to the forefront. The peptide-based approach represents a turning point as peptides have demonstrated unique features of selectivity and specificity towards specific targets.
DRIVER: Increasing use of peptides in pharmaceutical drugs
Peptides are highly active and highly specific drug substances. Due to the diversity of their biological functions, they are used in an extensive range of therapeutic areas. Peptides are increasingly entering drug development pathways as potential active pharmaceutical ingredients due to their large chemical space, high biological activity, high specificity, relative ease of synthesis, ready availability, and low toxicity.Oncology, diabetes, and obesity are three prominent therapeutic areas where peptides generate billions of dollars in revenues.
RESTRAINT: Lack of a unified set of regulations for therapeutic peptides
Peptide-based drugs fall in the range of small-molecule and large-molecule biologics. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Most of these drugs are chemically synthesized. Though the synthesis process for different peptide drugs is similar, their action mechanisms vary widely. Hence, developing a unified set of regulatory guidelines that can effectively address the safety and quality requirements for such a diverse group of molecular entities with various unique mechanisms of action is a challenging task. There are no formal guidelines from any regulatory agency for developing this class of therapeutics.
OPPORTUNITY: Development of personalized medicines
Interest in personalized treatment has been fueled by the concept of tailored therapy with the best response and highest safety margin to ensure better patient care. Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of various tissues, either in the normal or diseased state. Personalized proteomics or proteomic profiling is the next big step in personalized medicine; it provides clarity on disease pathomechanisms. To boost the use of proteomics in personalized medicine, scientists proposed the development of a user-friendly platform to program electrochemically directed peptide synthesis based on a microfluidic multiplexing system controlled by software under the ElectroMed project funded by the European Union. The ligand-receptor complexes will then be detected and quantified by label-free sensors based on nanomaterials.
Geographical Growth Dynamics: The Asia Pacific region is the fastest-growing region of the peptide synthesis market in 2020.
Based on the region, the peptide synthesis market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is expected to register the highest CAGR in the peptide synthesis market during the forecast period. Growing R&D funding, increasing investments by pharmaceutical and biotechnology companies, and rising R&D activities in the region are expected to drive market growth.
Request Sample Pages@
Global Key Players:
Key players in the peptide synthesis market include Thermo Fisher Scientific (US), Merck KGaA (Germany), Kaneka Corporation (Japan), GenScript Biotech Corporation (China), and Bachem Holding AG (Switzerland).